A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT06136351 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Mantle-Cell

Interventions

DRUG: Zanubrutinib
DRUG: Rituximab
DRUG: Bendamustin

Sponsor

Ruijin Hospital